Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 août 2023 07h00 HE | Source: Pluri Inc.

Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of HealthPLX-R18 has the...
13 juil. 2023 02h00 HE | Source: Pluri Inc.

Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote...
11 juil. 2023 02h00 HE | Source: Pluri Inc.

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear incident.The work specified by the contract is...
27 avr. 2023 07h00 HE | Source: Pluri Inc.

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

Breakthrough system substantially increases cell production, with the potential to reach much higher productivity driven by platform’s significant scalability Flexible, industrial scale cell...
13 mars 2023 08h00 HE | Source: Pluri Inc.

Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

HAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
22 déc. 2022 07h00 HE | Source: Pluri Inc.

Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept

Milestones over the last year include launch of new Company strategy, joint venture with Tnuva Group in the field of cultivated meat and additional biologics technology partnership;Joint venture with...
15 déc. 2022 16h05 HE | Source: Pluri Inc.

Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

HAIFA, Israel, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, announced today that it has signed securities...
10 nov. 2022 07h00 HE | Source: Pluri Inc.

Pluri wins BioTech Breakthrough Cell Innovation of the Year Award

HAIFA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company” (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
31 oct. 2022 08h00 HE | Source: Pluri Inc.

Pluri to Present and Participate in Upcoming Conferences

HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company,...
29 sept. 2022 07h00 HE | Source: Pluri Inc.

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

New company strategy will reduce cash burn by approximately 30%, with $56M in cash on consolidated balance sheetLeading European manufacturer of active pharmaceutical ingredients (APIs) to use Pluri’s...

Page précédente

Page suivante